All In Biotech

Free tool

FAERS Monitor: Cordran

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 016455 or its brand name (Cordran, Flurandrenolide). Reports on generic versions are filed under their own applications.

Reports

333

Serious

152

46% of reports

Hospitalization

43

Death reported

6

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pruritus31
  • drug ineffective30
  • headache20
  • nausea20
  • rash19
  • fatigue18
  • pain18
  • diarrhoea16
  • psoriasis16
  • depression14
  • dyspnoea14
  • pain in extremity14
  • off label use13
  • anxiety12
  • dizziness12

Reports by year received

View as table
YearReports
20043
20051
20064
20072
20091
20104
20116
20124
20139
201411
201524
201620
201731
201822
201931
202024
202118
202222
202327
202420
202522
202627

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,826 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
psoriasisSignal167.74.888
pruritusSignal315.13.6100
depressionSignal143.92.327
pain in extremitySignal143.01.817
rashSignal192.81.820
anxietySignal122.71.511
headacheSignal202.01.310
pain181.91.26
nausea201.61.04
diarrhoea161.61.03
dyspnoea141.60.92
dizziness121.50.92
fatigue181.50.92
drug ineffective301.41.04
off label use130.90.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.